BofA upgraded Beam Therapeutics (BEAM) to Buy from Neutral with a $42 price target
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Beam announces FDA clearance of BEAM-302 investigational new drug application
- Cathie Wood’s ARK Investment buys 143K shares of Beam Therapeutics today
- Promising Data and Future Potential Drive Buy Rating for Beam Therapeutics
- Cathie Wood Buys the Dip in Baidu Stock (BIDU) and Sells Roblox
- Strategic Advantage and Exclusive Rights Bolster Beam Therapeutics’ Buy Rating